Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity.

eLife·2026
Same author

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.

Gynecologic oncology·2026
Same author

Peptidoglycan remodeling improves salt resilience of <i>Zymomonas mobilis</i>.

Applied and environmental microbiology·2026
Same author

Advancing precision health discovery in a genetically diverse health system.

Cell·2026
Same author

Genome-wide classification of tumor-derived reads from bulk long-read sequencing.

bioRxiv : the preprint server for biology·2026
Same author

The zinc bound form of the actinomycete derived natural product compound JBIR-141 induces a mitotic phenotype in fission yeast.

Scientific reports·2025

Related Experiment Video

Updated: Mar 8, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K

Circulating-tumor DNA as an early detection and diagnostic tool.

Timothy M Butler1, Paul T Spellman1, Joe Gray2

  • 1Oregon Health and Science University Knight Cancer Institute, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, United States; Oregon Health and Science University Department of Molecular and Medical Genetics, 3181 SW Sam Jackson Park Road L103, Portland, OR 97239-3098, United States.

Current Opinion in Genetics & Development
|January 28, 2017
PubMed
Summary

New circulating-tumor DNA (ctDNA) tests offer non-invasive cancer genotyping and treatment monitoring. These sensitive methods detect minimal residual disease, predicting recurrence early for improved patient care.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K

Related Experiment Videos

Last Updated: Mar 8, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Advancements in circulating-tumor DNA (ctDNA) analysis have spurred numerous clinical studies.
  • ctDNA enables non-invasive cancer mutation characterization, avoiding invasive biopsies.

Purpose of the Study:

  • To review key recent studies in the ctDNA field.
  • To discuss future advancements in ctDNA analysis for enhanced patient care.

Main Methods:

  • Review of recent literature on ctDNA analysis techniques.
  • Highlighting studies demonstrating clinical applications of ctDNA.

Main Results:

  • ctDNA analysis facilitates non-invasive genotyping of target mutations.
  • Serial ctDNA monitoring assesses treatment response and resistance mechanisms.
  • Sensitive ctDNA detection of minimal residual disease predicts recurrence before clinical symptoms.

Conclusions:

  • ctDNA analysis presents significant clinical utility in oncology.
  • Future improvements in ctDNA technology will further benefit patient management and outcomes.